Health Care • Biotechnology: Pharmaceutical Preparations
$45.06 ▲ +0.07
(+0.16%)
MKT CAP: $4.03B • VOL: 2.09M
52W L $22 52W H $94
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$38
MEDIAN
$50
MEAN
$51
HIGH
$61
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE LQDA TAPE
LQDA // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $54.52 | $51.82 | 2025-02-14 | $41.00 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $56.78 | $53.17 | 2025-02-06 | $42.36 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $51.37 | $49.57 | 2025-01-29 | $43.26 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $45.96 | — | 2025-01-17 | $44.16 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $39.65 | $42.81 | 2025-01-09 | $40.10 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $53.62 | $46.86 | 2024-12-18 | $39.20 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $43.71 | $45.51 | 2024-12-04 | $41.91 | -4.3% | 48% | C |